Zwangsstörungen

U. Voderholzer

doi:10.1055/s-2004-830294

Fortschritte der Neurologie · Psychiatrie, Inhaltsverzeichnis

Fortschr Neurol Psychiatr 2005; 73(9): 526-547
DOI: 10.1055/s-2004-830294

Fort- und Weiterbildung

Zwangsstörungen

Obsessive-Compulsive DisordersU. Voderholzer¹

¹Abt. für Psychiatrie und Psychotherapie der Uniklinik Freiburg

Abstract

Volltext

Referenzen

Literatur

1 Kessler R, McGonagle K, Zhao S. et al . Lifetime and 12-month prevalence of DSM-II-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psych. 1994; 51 8-19
2 Bebbington P E. Epidemiology of obsessive-compulsive disorder. The British Journal of Psychiatry. 1998; 173 (suppl 35) 2-6
3 Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder. Archives of General Psychiatry. 1999; 56 121-127
4 Hohagen F. Zwangsstörungen. In: Berger M (ed). Psychiatrie und Psychotherapie. München: Urban & Schwarzenberg 1999
5 Broocks A, Hohagen F. Obsessive-Compulsive Disorder. In: Smelser NJ, Baltes PB (eds). The International Encyclopedia of the Social and Behavioral Sciences. Amsterdam: Elsevier 2001
6 Berger M, Voderholzer U, Hohagen F. Obsessive-compulsive disorder: an underestimated disorder. In: Maj E, Sartorius N, Okasha A, Zohar J (Hrsg.) WPA Series Evidence and Experience in Psychiatry. 2000 4: 297-299
7 Baer L, Jenike M A. Personality disorders in obsessive compulsive disorder. Psychiatr Clin North Am. 1992; 15 803-812
8 Pigott T A, L'Heureux F, Dubbert B, Bernstein S, Murphy D L. Obsessive compulsive disorder: comorbid conditions. J Clin Psychiatry. 1994; 55 Suppl 15-32
9 Thiel A, Broocks A, Ohlmeier M, Jacoby G E, Schussler G. Obsessive-compulsive disorder among patients with anorexia nervosa and bulimia nervosa. Am J Psychiatry. 1995; 152 72-75
10 Overbeek T, Schruers K, Vermetten E, Griez E. Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. J Clin Psychiatry. 2002; 63 1106-1112
11 Regier D A, Boyd J H, Burke J D Jr. et al . One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1998; 45 977-986
12 Poyurovsky . et al . Obsessive-Compusive Disorder in Schizophrenia. Clinical Characteristics and Treatment. CNS Drugs. 2004; 18 989-1010
13 Kano Y, Ohta M, Nagai Y. Clinical characteristics of Tourette syndrome. Psychiatry Clin Neurosci. 1998; 52 51-57
14 Petter T, Richter M A, Sandor P. Clinical features distinguishing patients with Tourette's syndrome and obsessive-compulsive disorder from patients with obsessive-compulsive disorder without tics. J Clin Psychiatry. 1998; 59 456-459
15 Baer L, Jenike M A, Ricciardi J N. et al . Standardized assessment of personality disorders in obsessive-compulsive disorder. Arch Gen Psychiatry. 1990; 47 826-830
16 Summerfeldt L J, Huta V, Swinson R P. Personality and obsessive-compulsive disorder. In: Swinson RP, Antony MM, Rachman S, Richter MA. Obsessive-Compulsive Disorder. Theory, research, and treatment. New York, London: The Guilford Press 1998: 79-119
17 Swinson R P, Antony M M, Rachman S, Richter M A. Obsessive-Compulsive Disorder. Theory, research, and treatment. New York: Guilford Press 1998
18 Stengler-Wenzke K, Beck M, Holzinger A, Angermeyer M C. Stigmatisierungserfahrungen von Patienten mit Zwangserkrankungen. Fortschr Neurol Psychiat. 2004; 72 7-13
19 Baxter L R. Neuroimaging studies of obsessive compulsive disorder. Psychiatr Clin North Am. 1992; 15 871-884
20 Schwartz J M, Stoessel P W, Baxter L R, Martin K M, Phelps M E. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1996; 53 109-113
21 Ebert D, Speck O, Konig A, Berger M, Hennig J, Hohagen F. 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Res. 1997; 74 173-176
22 Bartha R, Stein M B. et al . A short echo ¹H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. Am J Psychiatry. 1998; 155 1584-1591
23 Nicolson R, Swedo S E, Lenane M. et al . An open trial of plasma exchange in childhood-onset obsessive-compulsive disorder without poststreptococcal exacerbations. J Am Acad Child Adolesc Psychiatry. 2001; 39 1313-1315
24 Murphy D L, Greenberg B, Altemus M, Benjamin J, Grady T, Pigott T. The Neuropharmacology and Neurobiology of Obsessive-compulsive Disorder. In: Westenberg HGM (ed). Advances in the Neurobiology of Anxiety Disorders. John Wiley & Sons 1996a: 279-297
25 Pigott T A, Seay S M. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry. 1999; 60 101-106
26 Hoehn-Saric S R, Ninan P, Black D W. et al . Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000; 57 76-82
27 Stein D J. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry. 2000; 47 296-304
28 Pato M T, Zohar-Kadouch R, Zohar J, Murphy D L. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry. 1991; 145 1521-1525
29 Benkelfat C, Murphy D L, Zohar J. et al . Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry. 1989; 46 23-28
30 Broocks A, Pigott T A, Hill J L. et al . Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results. Psychiatry Res. 1998c; 79 11-20
31 Hollander E, DeCaria C M, Nitescu A. et al . Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 1992; 49 21-28
32 Hollander E, Fay M, Cohen B. et al . Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry. 1988; 145 1015-1017
33 Zohar J, Mueller E A, Insel T R. et al . Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry. 1987; 44 946-951
34 Hollander E, DeCaria C, Nitescu A. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to m-CPP in obsessive-compulsive disorder. Psychiatry Research. 1992; 36 1-17
35 Zohar J, Insel T R, Zohar Kadouch R C. et al . Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry. 1988; 45 167-172
36 Billet E A, Richter M A, Kennedy J L. Genetics of obsessive-compulsive disorder. In: Swinson RP, Antony MM, Rachman S, Richter MA. Obsessive-Compulsive Disorder. Theory, research, and treatment. New York: Guilford Press 1998: 181-206
37 Zohar J, Kennedy J L, Hollander E, Koran L M. Serotonin-1D Hypothesis of Obsessive-Compulsive Disorder: An update. J Clin Psychiatry. 2004; 65 18-21
38 Kuelz A K, Hohagen F, Voderholzer U. Neuropsychological performance in obsessive-compulsive disorder: a critical review. Biological Psychology. 2004; 65 185-236
39 Voderholzer U, Kuelz A K. Psychotherapy and pharmacotherapy of obsessive-compulsive disorder: New findings. 13th Congress of the Association of European Psychiatrists. 2005 (Abstract)
40 Berger M. Psychische Erkrankungen. Klinik und Therapie. 2. Aufl. München: Urban & Fischer 2004
41 Abramowitz J S. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 1997; 65 44-52
42 Hohagen F, Berger M. New perspectives in research and treatment of obsessive-compulsive disorder. Br J Psychiatry. Suppl 1998; 35 1-11
43 Foa E B, Liebowitz M R, Kozak M J. et al . Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramin, and Their CombiNation in the Treatment of Obsessive-Compulsive Disorder. Am J Psychiatry. 2005; 162 151-161
44 Kordon A, Kahl K G, Broocks A. et al . Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. European Archives of Psychiatry & Clinical Neuroscience. Feb 2005; 255 48-50
45 Rufer M, Hand I, Braatz A. et al . A prospective study of alexithymia in obsessive-compulsive patients treated with multimodal cognitive-behavioral therapy. Psychother Psychosom. 2004; 73 101-106
46 Abramowitz J S. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol. 1997; 65 44-52
47 Kobak K A, Greist J H, Jefferson J W, Katzelnick D J, Henk H J. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology. 1998; 136 205-216
48 Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995; 166 424-443
49 Stein D J, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995; 10 11-18
50 Bergqvist P B, Bouchard C, Blier P. Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. Biological Psychiatry. 1999; 45 164-174
51 Hohagen F, Winkelmann G, Rasche R H. et al . Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry. 1998; Suppl 35 71-78
52 Kordon A, Kahl K G, Broocks A. et al . Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. European Archives of Psychiatry & Clinical Neuroscience. Feb 2005; 255 48-50
53 Geller D A, Biederman J, Stewart S E. et al . Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry. 2003; 160 1919-1928
54 Hoehn-Saric S R, Ninan P, Black D W. et al . Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000; 57 76-82
55 Poyurovsky . et al . Obsessive-Compusive Disorder in Schizophrenia. Clinical Characteristics and Treatment. CNS Drugs. 2004; 18 989-1010
56 The C lomipramine. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991; 48 730-738
57 Tollefson G D, Rampey A H, Potvin J H. et al . A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994; 51 559-567
58 Greist J H, Jefferson J W, Kobak K A. et al . A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995; 10 57-65
59 Hollander E, Koran L M, Goodman W K. et al . A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003; 64 640-647
60 Hollander E, Allen A, Steiner M. et al . Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry. 2003; 64 113-121
61 Montgomery S A, Kasper S, Stein D J. et al . Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001; 16 75-86
62 Bystritsky A, Ackerman D L, Rosen R M. et al . Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry . 2004; 65 565-568
63 Denys D, de Geus F, van Megen H J, Westenberg H G. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004; 65 1040-1048
64 McDougle C J, Goodman W K, Leckman J F. et al . Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994; 51 302-308
65 Hollander E, Baldini-Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003; 6 397-401
66 Shapira N A, Ward H E, Mandoki M. et al . A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004; 55 553-555

PD Dr. med. Ulrich Voderholzer

Abteilung für Psychiatrie und Psychotherapie Universität Freiburg

Hauptstraße 5

79104 Freiburg

eMail: ulrich_voderholzer@psyallg.ukl.uni-freiburg.de